CRISPR tech market to reach $1.72m by 2023: report
23-11-2018
Allergan to pay Editas $90m for development of CRISPR eye treatment
20-03-2017
Are the Broad Institute’s CRISPR patents too broad?
29-10-2015
jansucko / iStockphoto.com
US company KSQ Therapeutics, a specialist in using CRISPR for drug development, has raised $80 million in series C funding.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
CRISPR, funding, KSQ Therapeutics, drug candidates, CRISPRomics, drug discovery, T-cell immunotherapy, Flagship Pioneering, Polaris Partners
